Trial Profile
Phase II Study of ET-743 [trabectedin] Therapy in Metastatic Osteosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2010
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary)
- Indications Osteosarcoma
- Focus Adverse reactions; Therapeutic Use
- 17 Dec 2009 Inclusion and exclusion criteria amended from NCT.
- 17 Dec 2009 Actual end date (Sep 2003) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.